Benign Prostatic Hypertrophy
Indicated for treatment of signs and symptoms of benign prostatic hyperplasia (BPH)
0.4 mg PO qDay; take 30 minutes after same meal each day
If inadequate response after 2-4 weeks, may increase to 0.8 mg qDay
If therapy interrupted or discontiniued for several days, resume at 0.4 mg/day and increase if needed
Bladder Outlet Obstruction (Off-label)
Relief of symptoms
0.4 mg PO qDay
Ureteral Stones (Off-label)
Facilitation of kidney stone expulsion
0.4 mg PO qDay; discontinued after successful expulsion (average, 1-2 weeks).
Signs and symptoms of orthostasis, including syncope
Infrequent reports of dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, and tachycardia
During cataract and glaucoma surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha1 blocker therapy
Skin desquamation including reports of Stevens-Johnson syndrome, erythema multiforme, and dermatitis exfoliative
Constipation, vomiting, and epistaxis.
Allergic-type reactions (eg, skin rash, urticaria, pruritus, angioedema, respiratory symptoms) have been reported with positive rechallenge.